Interaction of Ginkgo biloba with efavirenz

AIDS

Volumn 23, Issue 9, 2009, Pages 1184-1185

  Wiegman, Dirk Jan ^a   Brinkman, Kees ^a   Franssen, Eric J F ^a  

^a Department of Clinical Pharmacy ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; EFAVIRENZ; EMTRICITABINE; GINKGO BILOBA EXTRACT; NEVIRAPINE; TENOFOVIR DISOPROXIL;

ADULT; CASE REPORT; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; HERB DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT FAILURE; VIRUS LOAD;

BENZOXAZINES; DRUG INTERACTIONS; GINKGO BILOBA; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS;

EID: 67651097952     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832c412b     Document Type: Letter

References (7)

1. Van den Bout-van den Beukel CJ, Koopmans PP, van der Ven AJ, De Smet PA, Burger DM. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab Rev 2006; 38:477-514.
2. Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir diso-proxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 2007; 8:371-382.
3. Zhao Y, Wang L, Bao Y, Li C. A sensitive method for the detection and quantification of ginkgo flavonols from plasma. Rapid Commun Mass Spectrom 2007; 21:971-981.
4. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycopro-tein. Drug Metab Rev 2004; 36:57-104.
5. Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 2008; 56:5366-5373.
6. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E. Herb-drug interactions: a literature review. Drugs 2005; 65:1239-1282.
7. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-36.